Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Joubert

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Joint Bone Spine|February 20, 2017
Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trialFrancis Berenbaum, Thao Pham, Pascal Claudepierre, et al.
RMD Open|January 21, 2020
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational studyAlain Saraux, René-Marc Flipo, Francis Fagnani, et al.
The Journal of Rheumatology|January 18, 2011
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysisRobert Launois, Bernard Avouac, Francis Berenbaum, et al.
Joint Bone Spine|August 2, 2015
Impact of rheumatoid arthritis on career progression, productivity, and employability: The PRET StudyPhilippe Bertin, Francis Fagnani, Anne Duburcq, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR studyAlain Saraux, Bernard Combe, Francis Fagnani, et al.
Plos One|December 5, 2014
Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative studyFrancis Berenbaum, Pierre Chauvin, Christophe Hudry, et al.
Journal of the American Medical Informatics Association : JAMIA|December 1, 2012
Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR projectPaul Avillach, Jean-Charles Dufour, Gayo Diallo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL StudyRobert Launois, Elise Cabout, Daniel Benamouzig, et al.
International Journal of Medical Informatics|December 27, 2005
Health search engine with e-document analysis for reliable search resultsArnaud Gaudinat, Patrick Ruch, Michel Joubert, et al.
Annals of the Rheumatic Diseases|November 6, 2017
Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaireLaure Gossec, Pierre Chauvin, Alain Saraux, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Joint Bone Spine|February 20, 2017
Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trialFrancis Berenbaum, Thao Pham, Pascal Claudepierre, et al.
RMD Open|January 21, 2020
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational studyAlain Saraux, René-Marc Flipo, Francis Fagnani, et al.
The Journal of Rheumatology|January 18, 2011
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysisRobert Launois, Bernard Avouac, Francis Berenbaum, et al.
Joint Bone Spine|August 2, 2015
Impact of rheumatoid arthritis on career progression, productivity, and employability: The PRET StudyPhilippe Bertin, Francis Fagnani, Anne Duburcq, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR studyAlain Saraux, Bernard Combe, Francis Fagnani, et al.
Plos One|December 5, 2014
Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative studyFrancis Berenbaum, Pierre Chauvin, Christophe Hudry, et al.
Journal of the American Medical Informatics Association : JAMIA|December 1, 2012
Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR projectPaul Avillach, Jean-Charles Dufour, Gayo Diallo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL StudyRobert Launois, Elise Cabout, Daniel Benamouzig, et al.
International Journal of Medical Informatics|December 27, 2005
Health search engine with e-document analysis for reliable search resultsArnaud Gaudinat, Patrick Ruch, Michel Joubert, et al.
Annals of the Rheumatic Diseases|November 6, 2017
Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaireLaure Gossec, Pierre Chauvin, Alain Saraux, et al.
Pageof 7